Behind the Breakthroughs - Podcasts
Podcast

Behind the Breakthroughs

Inside Precision Medicine
0 Plays

Join host Jonathan D. Grinstein, PhD, North American Editor for Inside Precision Medicine , as he uncovers the stories behind the pioneers driving the precision medicine revolution. Behind the Breakthroughs features candid interviews with seasoned veterans and rising stars, exploring their origin stories and groundbreaking contributions advancing the frontiers of patient diagnosis, treatment, and care. In every episode, Jonathan goes beyond the science, diving deep into the personal and professional journeys of those striving to make these incredible new therapies more equitable and accessible globally. You'll discover how emerging technologies in molecular diagnostics, next-generation sequencing, genetic medicines (e.g., cell and gene therapies), and AI/ML are transforming treatment and bringing precision medicine closer to the forefront of healthcare. Whether you’re a researcher at a large pharma company or small biotech startup, a clinician at a major h

Latest Episodes

Jagesh Shah: Will Nonviral Delivery Replace AAVs in Genetic Medicine?

18 Nov 2026
57:55

Genetic medicines hold enormous promise, but delivering them safely and precisely to the right cells remains a major challenge. In this episode of Behind the Breakthroughs, Mirai Bio's chief scientific officer, Jagesh Shah, PhD, discusses advances in targeted lipid nanoparticle (LNP) delivery, the safety trade-offs between viral and nonviral approaches, and whether nonviral technologies could eventually replace viral vectors. Produced and hosted by Jonathan D. Grinstein, PhD Audio mixed and mast…

Ryan Beal: Getting Under Cancer's Skin

04 Nov 2026
51:49

Dyve Biosciences is developing a technology to deliver drugs through the skin that conventional transdermal approaches cannot accommodate. Its lead oncology program, DV800, targets tumor acidity, a longstanding therapeutic challenge. In this episode of Behind the Breakthroughs, CEO Ryan Beal, MD, discusses the technology, its potential in cancer treatment, and how his own cancer experience reshaped his approach to drug development. Produced and hosted by Jonathan D. Grinstein, PhD Audio mixed an…

Hussam Al Kateb: Inside Mayo Clinic’s Genomic Diagnostics Revolution

21 Oct 2026
41:07

Mayo Clinic Laboratories’ new whole-transcriptome RNA sequencing assay expands the detection of clinically significant gene fusions across solid tumors, helping refine cancer diagnoses and inform targeted treatment decisions. Hussam Al Kateb, PhD, co-director of Mayo Clinic’s Clinical Genomics Lab, takes us behind the scenes of a major reference laboratory to explore the challenges of developing advanced genomic diagnostics, keeping pace with scientific discovery, and translating technological b…

Matt Begemann: The Cancer-Killing CRISPR

07 Oct 2026
46:26

What began as a search for plant-friendly CRISPR tools led Matt Begemann, PhD, and colleagues to Cas12a2, or CasCLEAR, an unusual system that can trigger broad nucleic acid damage after recognizing an RNA target, creating potential applications in cancer therapy, diagnostics, and antimicrobials. With early studies showing promise against cancer-causing mutations, Begemann’s story highlights both the challenges of translating Cas12a2 into therapies and the value of pursuing unexpected scientific …

Wei-Wu He: Craig Venter’s Legacy and the Future of Human Longevity

23 Sep 2026
1:02:00

Human Longevity executive chairman Wei-Wu He discusses how the integration of genomics, advanced imaging, and artificial intelligence could transform disease prediction and personalized preventive medicine. Reflecting on Craig Venter’s legacy, he explores the challenges of democratizing precision medicine and the quest to extend human healthspan by identifying and intervening in disease before symptoms emerge. Produced and hosted by Jonathan D. Grinstein, PhD Audio mixed and mastered by Erick Zi…

Palani Kumaresan: Roche Diagnostics Is Ramping Up—Should Illumina Be Worried?

09 Sep 2026
59:24

Roche’s AXELIOS sequencer, Alzheimer’s blood test, and push to automate mass spectrometry point to a broader strategy of making advanced diagnostics routine. Whether AXELIOS can meaningfully challenge Illumina’s sequencing dominance, however, remains an open question. Produced and hosted by Jonathan D. Grinstein, PhD Audio mixed and mastered by Erick Ziegler Brought to you by Inside Precision Medicine (SAGE Publishing) Medicine is full of breakthroughs. Most don't become medicine. Behind the Bre…

Ken Greenberg: Can Ultrasound Shatter the Gene Therapy Delivery Bottleneck?

26 Aug 2026
51:45

Gene therapy’s biggest bottleneck remains delivery: getting increasingly sophisticated genetic medicines safely into the right cells. SonoThera is taking a radically different approach, using ultrasound and microbubbles instead of viral vectors and nanoparticles, which could allow for larger payloads, repeat dosing, and precise tissue targeting. The key question is whether this seemingly too-good-to-be-true approach can work in humans after promising results across multiple organs in animals. Pr…

David Thaisrivongs: Goldilocks and the First Oral PCSK9 Inhibitor

12 Aug 2026
42:00

Biocatalysis has evolved from a scientific curiosity into a powerful manufacturing platform, culminating in enlicitide, the first oral macrocyclic peptide PCSK9 inhibitor. Merck’s David Thaisrivongs explains how enzyme engineering helped create this “Goldilocks” class of medicines—and could open previously inaccessible drug targets to oral therapies. Produced and hosted by Jonathan D. Grinstein, PhD Audio mixed and mastered by Erick Ziegler Brought to you by Inside Precision Medicine (SAGE Publi…

Beaubrun and Acharya: No Antibiotic Without a Diagnostic

29 Jul 2026
57:29

Antimicrobial resistance (AMR) isn't going to be solved by new antibiotics alone—it also requires identifying resistant infections quickly enough to guide treatment and prevent transmission. In this episode of Behind the Breakthroughs, Anne Beaubrun, PhD, of Cepheid and Amish Acharya, PhD, of the Fleming Initiative, discuss how rapid molecular diagnostics, including the TRACE-CPE study, could bring precision medicine to infectious disease by enabling earlier detection of carbapenemase-producing …

Amit Etkin: Precision Psychiatry’s Future Isn’t Genomics—It’s Brain Activity

15 Jul 2026
1:00:32

For decades, psychiatry has relied on symptom-based diagnosis and trial-and-error treatment, but precision medicine is set to transform mental health care by using objective biological measures—such as EEG, sleep and circadian rhythm data, and cognitive testing—with AI-driven analysis to match patients with the therapies most likely to work for them. In this episode of Behind the Breakthroughs, Alto Neuroscience founder and CEO Amit Etkin explains how biomarker-guided drug development and biolog…

Michael Antonov: From Virtual World Builder to Real-World Drug Designer

01 Jul 2026
1:02:09

AI is transforming biomedical research, but meaningful advances in drug discovery require more than just increasingly powerful algorithms—they depend on combining machine learning with physics-based simulations, mechanistic models, and rigorous experimental validation. In this episode of Behind the Breakthroughs, Michael Antonov, co-founder of Oculus and computational drug discovery company Deep Origin, shares a pragmatic perspective on AI's opportunities and limitations in medicine, explaining …

Philippe Pouletty: Turning Europe’s Life Science Startups Into World Leaders

17 Jun 2026
58:32

Philippe Pouletty, MD, is one of Europe’s most successful life sciences entrepreneurs, having spent more than 30 years building category-leading biotechnology and medical technology companies from breakthrough scientific innovations. His most notable achievement is Abivax, which he founded and chaired for a decade, transforming it into a global biotechnology leader that reached an approximately $10 billion market capitalization following positive Phase 3 results in 2025. Today, he is applying th…

Arthur Caplan: The Right to Life, Liberty, and Pursuit of Health

03 Jun 2026
1:00:54

While growing up during the polio era, Arthur Caplan, PhD, saw doctors hide painful truths from families and children, which sparked his lifelong questions about power, protection, and inequality in medicine. In this episode, Caplan claims that bioethics has changed from marginalizing or abandoning disabled people to genetic testing, parental perfectionism, and personal autonomy over collective responsibility. Caplan predicts that extreme individualism will endanger public health and that the ne…

Carolina Aguilar: Brain-Computer Interfaces that Heal Neural Circuits

20 May 2026
54:44

Brain-computer interfaces have gained widespread attention largely for assistive applications, but Carolina Aguilar sees their greatest potential in directly treating neurological disease. Through INBRAIN Neuroelectronics, she is developing graphene-based implants designed to read and stimulate neural activity with far greater precision than conventional devices, building on insights from her 13 years at Medtronic and earlier neuroscience research. In this conversation, Aguilar explains why INBR…

Matthew Rabinowitz: Engineering a New Era of Diagnosis

06 May 2026
1:07:18

Matthew Rabinowitz, PhD, moved from engineering to medicine after his Human Genome Project work, motivated by both scientific insight and personal loss that exposed the limits of existing genetic diagnostics. He founded Natera and later Myome, building genomic and AI-driven tools to improve disease detection, risk assessment, and prevention. In the episode, he highlights challenges. such as regulatory barriers, fragmented data, and translating genetics into clinical decisions, while aiming to de…

Jurgi Camblong: Data-Driven Doctors Without Borders

22 Apr 2026
1:00:31

Precision medicine promises individualized care through data, but progress remains fragmented. Clinical, genomic, and imaging data are siloed, limiting real-world use. Jurgi Camblong, PhD, founded SOPHiA Genetics to integrate multimodal data into actionable insights, yet variability in technologies and evolving biology complicate standardization. In this episode of Behind the Breakthroughs, Camblong discusses how effective solutions require combining diverse AI methods grounded in context and lo…

Molly Gibson: Superintelligence and the Future of Drug Development

08 Apr 2026
51:25

As an Origination Partner at Flagship Pioneering, Molly Gibson, PhD, co-founded her first company, Generate:Biomedicines, in 2018, where she made her mark by developing models that design novel proteins—work that has already led to a Phase 3 asthma drug. Since then, she has gone on to co-found two additional companies: Expedition Medicines and Lila Biosciences. In this episode, Molly explains why the anticipated boom in AI-guided drug development hasn’t fully materialized and how she’s tackling …

Mike Curtis: Pig Organs as a Bridge to Human Transplants

25 Mar 2026
52:22

Xenotransplantation has long been a scientifically promising but ethically complex field, overshadowed by its limited practicality despite the growing shortage of transplantable organs and the urgent needs of patients. Recent breakthroughs, including genetically modified pig heart transplants in 2022 and 2023, have demonstrated its feasibility, marking a turning point even though long-term survival has not yet been achieved. In this episode of Behind the Breakthroughs, Mike Curtis, PhD, Presiden…

Markus Warmuth: Eliminating Pathogenic Proteins with Molecular Glue Degraders

11 Mar 2026
48:23

Traditional drugs usually inhibit specific protein sites, but many disease-causing proteins lack accessible or unique motifs, leaving them “undruggable.” Targeted Small-molecule drugs have long been the quiet workhorses of modern medicine, slipping inside cells to target disease-driving proteins, even as biologics, immunotherapies, and genetic medicines have taken center stage in recent years. Yet thousands of disease-related proteins remain “undruggable” because they lack the structural pockets…

Alicia Zhou: The Dark Matter for Cancer Immunotherapy Translation

25 Feb 2026
57:26

Cancer Research Institute CEO Alicia Zhou, PhD, traces her path from teenage lab technician to leader in cancer immunotherapy. Trained at MIT and Dana-Farber, she worked on The Cancer Genome Atlas before moving to industry at Color Genomics, expanding access to clinical sequencing. Zhou champions applying advanced genomics to immunotherapy through CRI’s Discovery Engine, an open dataset mapping tumor–immune interactions. She argues nonprofits uniquely fund shared infrastructure and standardizati…

Podcasts

Comments & Reviews0